Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 6/20 | 0.34 |
| ▸ | CCNC | P24863 | 5/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852884 | 0.90 | OTUD7B (0.39) | OTUD7BCALCRLNAMPTSPRCDK8 | |
| SCHEMBL18702126 | 0.80 | OTUD7B (0.43) | OTUD7BCALCRLSPRCDK8CCNC | |
| SCHEMBL19852880 | 0.80 | OTUD7B (0.43) | OTUD7BCALCRLSPRCRBNCDK8 | |
| SCHEMBL19852881 | 0.80 | OTUD7B (0.43) | OTUD7BCALCRLSPRCRBNCDK8 | |
| SCHEMBL29360897 | 0.80 | OTUD7B (0.43) | OTUD7BCALCRLSPRCDK8CCNC | |
| SCHEMBL24339014 | 0.78 | OTUD7B (0.39) | OTUD7BCALCRLSPRCRBNCDK8 | |
| SCHEMBL18711886 | 0.78 | OTUD7B (0.46) | OTUD7BSPRCDK8CCNCJAK1 | |
| SCHEMBL2338577 | 0.77 | CCNC (0.49) | OTUD7BCRBNCDK8CCNC | |
| SCHEMBL4072997 | 0.76 | OTUD7B (0.47) | OTUD7BCALCRLSPRCRBNCDK8 | |
| SCHEMBL19852883 | 0.75 | ITGB3 (0.42) | OTUD7BCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8329904-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329904-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329904-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2430023-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | OTUD7B 1916/4885CALCRL 768/4885NAMPT 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.